Sildenafil and Revatio: How the Brand Relates to the Drug

What Is the Relationship Between Sildenafil and Revatio?

REVATIO is a branded medicine whose pharmacologically active moiety is sildenafil. The product is manufactured using sildenafil citrate, while its strengths are expressed as equivalent amounts of sildenafil.

Sildenafil identifies the drug responsible for PDE5 inhibition. REVATIO identifies a particular regulated product family built around that drug, with its own PAH indication, formulations and labeling.

The relationship can therefore be summarized as sildenafil being broader than REVATIO: every REVATIO product contains sildenafil, but not every sildenafil product is REVATIO.

Sildenafil Is the Active Ingredient in Revatio

REVATIO's pharmacological activity comes from sildenafil. Sildenafil inhibits phosphodiesterase type 5, or PDE5, and alters cGMP signaling in relevant vascular smooth-muscle tissues.

The current REVATIO label describes its dosage forms as containing sildenafil citrate equivalent to specified amounts of sildenafil. This distinction prevents salt mass from being confused with the labeled active-moiety strength.

The brand name does not create a different active molecule. Detailed salt-versus-active-moiety terminology is covered on the sildenafil citrate page, while target pharmacology belongs on the sildenafil PDE5 inhibition page.

Brand Name vs Active-Drug Name

Sildenafil is an established drug name, while REVATIO identifies a particular branded sildenafil product family. The two terms therefore should not be used as exact synonyms.

Generic products can contain sildenafil and reference the PAH product framework without carrying the REVATIO brand name. Sildenafil also appears in products intended for different labeled indications.

Using the active ingredient name identifies the molecule; using the brand name identifies a particular regulatory and commercial product.

Revatio Is a Product and Label Context

REVATIO is not simply another word for sildenafil. It is a regulated U.S. product family whose prescribing information defines its indication, populations, dosage forms, strengths, administration routes, contraindications and warnings.

Current labeling covers adults and pediatric patients 1 to 17 years old with WHO Group I pulmonary arterial hypertension. The formulation family includes oral tablets, powder for oral suspension and intravenous injection.

A common regulatory-history confusion comes from the label phrase "Initial U.S. Approval: 1998." That date refers to sildenafil's initial U.S. approval; REVATIO itself was first approved as a PAH tablet product in 2005.

The broader approval chronology remains on the sildenafil FDA approval history page.

Revatio and Pulmonary Arterial Hypertension

Current U.S. REVATIO labeling is specific to pulmonary arterial hypertension, or PAH, classified as World Health Organization Group I. It should not be generalized to every form of pulmonary hypertension.

For adults, the labeled indication is treatment of WHO Group I PAH to improve exercise ability and delay clinical worsening.

For pediatric patients 1 to 17 years old, REVATIO is indicated to improve exercise ability and, in children too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvement in exercise.

Clinical-trial evidence and disease-specific interpretation belong on the sildenafil for pulmonary arterial hypertension page.

Does Revatio Have a Different Mechanism From Sildenafil?

No separate molecular mechanism is created by the REVATIO brand. Its primary pharmacology comes from sildenafil-mediated PDE5 inhibition.

In pulmonary vascular smooth muscle, PDE5 inhibition reduces cGMP breakdown. Greater cGMP signaling promotes vascular smooth-muscle relaxation and pulmonary vasodilation.

What changes with REVATIO is the product and indication context rather than the identity of the molecular target. A full pathway explanation remains on the sildenafil NO–cGMP pathway page.

What Formulations Are Associated With Revatio?

Current U.S. REVATIO labeling includes three dosage-form contexts: a 20 mg oral tablet, powder for oral suspension that becomes 10 mg/mL after reconstitution and an intravenous injection containing 10 mg in 12.5 mL.

These products share sildenafil as the active drug but differ in physical form, route and handling requirements.

Formulation therefore matters within the REVATIO brand family even though it does not create a different molecular mechanism. The broader dosage-form map is covered on the sildenafil formulations page.

Revatio Tablet Context

The current REVATIO tablet is a film-coated oral product containing sildenafil citrate equivalent to 20 mg of sildenafil.

The 20 mg REVATIO tablet belongs to the PAH product context. It should not be conflated with the 25 mg, 50 mg and 100 mg tablet strengths commonly associated with ED-oriented sildenafil products.

The distinction is regulatory and product-specific rather than evidence that the sildenafil molecule itself differs. General tablet formulation information remains on the sildenafil tablets page.

Revatio Oral Suspension Context

REVATIO for oral suspension is supplied as powder rather than as a finished ready-to-use liquid. After labeled reconstitution, the suspension contains 10 mg sildenafil per mL.

Current labeling describes a final reconstituted volume of 112 mL. The product has its own preparation, storage and handling instructions, so the term oral suspension should not be interpreted as interchangeable with every sildenafil liquid product.

REVATIO powder for oral suspension should also be distinguished from LIQREV, a separately approved ready-to-use sildenafil oral suspension. Detailed formulation differences remain on the sildenafil oral suspension page.

Revatio Injection Context

REVATIO injection is the intravenous formulation within the brand family. Current labeling describes a clear, colorless, sterile, ready-to-use solution supplied in a single-dose vial.

The product contains 10 mg sildenafil in 12.5 mL, corresponding to 0.8 mg/mL. Current dosage information for the IV formulation is specifically provided for adults.

Current labeling also provides a product-specific pharmacologic bridge between routes: 10 mg IV is predicted to provide the pharmacological effect of sildenafil plus its N-desmethyl metabolite equivalent to a 20 mg oral dose.

That statement is not a universal oral-to-IV conversion and does not establish an injectable ED route. Route-specific comparison remains on the oral vs injectable sildenafil page.

Formulation and Indication Are Different Concepts

Formulation describes how REVATIO is physically supplied and administered, while indication describes the clinical condition for which the product is approved.

REVATIO demonstrates that one product family can include multiple routes and dosage forms while remaining inside one central WHO Group I PAH indication framework.

Conversely, sharing the sildenafil active ingredient with another product does not transfer REVATIO's indication or formulation labeling to that product.

Why Sildenafil Is Broader Than Revatio

Sildenafil is an active drug that appears across multiple branded and generic products. REVATIO is only one product family containing it.

Generic sildenafil products exist in both PAH-oriented and ED-oriented contexts, while other branded products use sildenafil for their own approved indications and formulations.

REVATIO should therefore not be used as a synonym for all sildenafil, and sildenafil should not automatically be interpreted using the REVATIO label.

How Viagra Helps Explain the Brand Relationship

VIAGRA and REVATIO both contain sildenafil, but they are different branded products with different U.S. indication and strength frameworks.

VIAGRA is associated with erectile dysfunction, while REVATIO is associated with WHO Group I pulmonary arterial hypertension. Sharing sildenafil does not make their labeling interchangeable.

Current REVATIO labeling specifically advises patients taking REVATIO not to take VIAGRA or other PDE5 inhibitors concurrently. The direct sildenafil–Viagra relationship is covered on the sildenafil and Viagra page, while full product comparison belongs on Viagra vs Revatio.

Does the Revatio Brand Change Sildenafil Pharmacokinetics?

A brand name does not create a new absorption, distribution, metabolism or elimination mechanism. Core sildenafil disposition remains determined by the active drug and the formulation through which it is delivered.

Within REVATIO itself, formulation and route matter. The oral tablet and suspension require gastrointestinal absorption, whereas the intravenous injection bypasses oral absorption and first-pass input.

The oral suspension and tablet also have product-specific bioequivalence evidence, while the IV formulation has its own labeled oral-versus-IV pharmacologic relationship. Those differences arise from formulation and route, not from the word REVATIO.

The broader technical ADME framework remains on the sildenafil pharmacokinetics page.

Safety Information Comes From Both Drug and Product Context

Because REVATIO contains sildenafil, its safety profile reflects sildenafil pharmacology, but the current REVATIO label also includes PAH- and product-specific warnings.

Current contraindications include concomitant organic nitrates, riociguat and known hypersensitivity to sildenafil or product components. Current warnings also address hypotension, pulmonary veno-occlusive disease, sudden vision or hearing loss, combination with other PDE5 inhibitors, priapism and vaso-occlusive crisis in pulmonary hypertension secondary to sickle cell disease.

Those points should be read within REVATIO's own label rather than copied uncritically from an ED product. Broader topics remain on the dedicated warnings, contraindications and drug interactions pages.

Riociguat Is an Important PAH-Related Safety Context

Riociguat is especially relevant to a REVATIO page because both medicines can appear in pulmonary vascular treatment discussions while acting on the cGMP signaling system through different molecular targets.

REVATIO inhibits PDE5 and reduces cGMP degradation, whereas riociguat stimulates soluble guanylate cyclase and increases cGMP signaling upstream.

Current U.S. REVATIO labeling lists concomitant riociguat use as a formal contraindication because PDE5 inhibitors can potentiate its hypotensive effects.

The dedicated sildenafil and riociguat interaction page explains that mechanism and regulatory status in detail.

Common Sildenafil and Revatio Terminology Confusion

One common misunderstanding is that REVATIO contains a different active drug from sildenafil. It does not: sildenafil is the pharmacologically active component.

Another is that every sildenafil product is REVATIO. Sildenafil appears in other branded and generic products with different indications, strengths and formulations.

A third confusion concerns the label's 1998 initial-approval statement. Sildenafil was initially approved in the United States in 1998, while the first REVATIO PAH tablet approval occurred in 2005.

A fourth mistake is to assume that every current REVATIO formulation applies to every labeled population. The current pediatric dosage section is oral, while the IV dosage section is specified for adults.

How to Understand the Sildenafil–Revatio Relationship

The most useful framework separates five layers: active moiety, drug-substance salt, brand, formulation and indication.

Sildenafil is the active moiety; sildenafil citrate is the salt used in REVATIO products; REVATIO is the brand; tablet, suspension and injection are dosage forms; and WHO Group I PAH defines the central current indication context.

Keeping those layers separate prevents several common errors, including treating all sildenafil as REVATIO, applying ED labeling to REVATIO or assuming that route and strength differences create a different active drug.

For the condition-specific evidence, continue to sildenafil for pulmonary arterial hypertension. For direct comparison with another sildenafil brand, use Viagra vs Revatio.